Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The CDCCs are strategically positioned in regions identified as high-impact areas
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
iSolveSM information on demand is the result of our focus on customer relationship
Subscribe To Our Newsletter & Stay Updated
